REGENXBIO Inc. (NASDAQ:RGNX) Receives $41.57 Consensus PT from Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNXGet Rating) have been given an average rating of “Hold” by the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $43.17.

Several brokerages have recently issued reports on RGNX. Zacks Investment Research lowered shares of REGENXBIO from a “buy” rating to a “hold” rating in a research note on Tuesday. Chardan Capital restated a “buy” rating on shares of REGENXBIO in a research note on Monday, April 11th. StockNews.com began coverage on shares of REGENXBIO in a research note on Thursday, March 31st. They set a “hold” rating for the company. TheStreet upgraded shares of REGENXBIO from a “d” rating to a “c” rating in a research note on Tuesday, March 1st. Finally, SVB Leerink decreased their price target on shares of REGENXBIO from $29.00 to $25.00 and set a “market perform” rating for the company in a research note on Wednesday, March 2nd.

Large investors have recently made changes to their positions in the business. Baillie Gifford & Co. bought a new position in REGENXBIO in the 1st quarter valued at $25,000. Point72 Hong Kong Ltd bought a new stake in shares of REGENXBIO during the 4th quarter worth $42,000. Meeder Asset Management Inc. lifted its holdings in shares of REGENXBIO by 1,558.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 1,443 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 1,356 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of REGENXBIO by 42.5% during the 2nd quarter. Royal Bank of Canada now owns 3,203 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 955 shares during the last quarter. Finally, Nkcfo LLC bought a new stake in shares of REGENXBIO during the 1st quarter worth $116,000. 87.57% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:RGNX traded up $1.05 on Friday, hitting $20.84. The stock had a trading volume of 443,782 shares, compared to its average volume of 385,382. The stock has a market cap of $898.83 million, a P/E ratio of 9.69 and a beta of 1.12. REGENXBIO has a 1 year low of $19.07 and a 1 year high of $46.46. The firm’s fifty day simple moving average is $28.99 and its two-hundred day simple moving average is $29.90.

REGENXBIO (NASDAQ:RGNXGet Rating) last posted its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported $6.67 EPS for the quarter, beating the consensus estimate of $4.28 by $2.39. The firm had revenue of $398.66 million during the quarter, compared to analyst estimates of $255.76 million. REGENXBIO had a net margin of 21.38% and a return on equity of 17.92%. The company’s revenue for the quarter was up 1759.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.24) EPS. Research analysts expect that REGENXBIO will post -4.47 EPS for the current fiscal year.

REGENXBIO Company Profile (Get Rating)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Featured Stories

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.